A new post-grant review at the Patent Trial and Appeal Board could be worth close attention for companies operating in the dental implant and medical device space. In PGR2026-00070, filed on August 11, 2026, the proceeding is captioned Straumann USA, LLC, signaling a challenge to a recently issued patent associated with one of the best-known names in dental technology.
At this stage, the docket entry identifies the matter by party name and PTAB number, but practitioners will want to watch for the petition and related filings to clarify the specific patent claims at issue, the identity of the petitioner, and the precise invalidity theories being advanced. In a post-grant review, however, the stakes are often broader than in inter partes review. PGR allows a challenger to raise a wider set of patentability defenses, including not only prior-art-based attacks under Sections 102 and 103, but also Section 112 issues such as written description, enablement, and indefiniteness, as well as subject-matter eligibility under Section 101 where appropriate.
That broader statutory toolkit is one reason this case may matter to patent prosecutors and in-house IP counsel. If the challenged patent is central to a product line, platform technology, or enforcement strategy, a PGR can become an early and aggressive vehicle for testing claim scope and specification support. For patent owners, these proceedings can expose vulnerabilities in drafting that would not necessarily be reachable in an IPR. For petitioners, they offer a chance to press multiple theories at once during the narrow window after patent issuance.
For life sciences and device companies in particular, any PTAB challenge involving Straumann is notable. The company’s portfolio sits in a commercially important and technically specialized sector, where claim construction, support for functional limitations, and distinctions over dense prior art can be outcome-determinative. If institution is granted, the case could provide useful guidance on how the Board approaches patentability challenges in this industry segment.
Patent practitioners should also monitor the case for procedural developments: whether the Board finds the petition sufficiently particularized, how the patent owner responds on discretionary and merits grounds, and whether expert declarations shape the institution decision. Even before a final written decision, those filings can offer valuable insight into PTAB strategy for newly issued medical-device patents.